https://orcid.org/0000-0002-4599-4729
References
- Woods NF, Mitchell ES. Symptoms during the perimenopause: prevalence, severity, trajectory, and significance in women’s lives. Am J Med. 2005;118(Suppl 12B):14–24.
- Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015;175(4):531–539.
- Freeman EW, Sammel MD, Sanders RJ. Risk of long-term hot flashes after natural menopause: evidence from the Penn Ovarian Aging Study cohort. Menopause. 2014;21(9):924–932.
- Hershman DL, Kushi LH, Shao T, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol. 2010;28(27):4120–4128.
- Ferreira AR, Di Meglio A, Pistilli B, et al. Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis. Ann Oncol. 2019;30(11):1784–1795.
- Lensen S, Archer D, Bell RJ, et al. A core outcome set for vasomotor symptoms associated with menopause: the COMMA (core outcomes in menopause) global initiative. Menopause. 2021;28(8):852–858.
- Carpenter JS. The hot flash related daily interference scale: a tool for assessing the impact of hot flashes on quality-of-life following breast cancer. J Pain Symptom Manage. 2001;22(6):979–989.
- Koo TK, Li MY. A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chirop Med. 2016;15(2):155–163.
- Peterson RA. A Meta-Analysis of cronbach’s coefficient alpha. J Consum Res. 1994;21(2):381.
- Nunnally JC. Psychometric theory—25 years ago and now. Educ Researcher. 1975;4(10):7–21.
- Fayers P, Machin D. Quality of life: The assessment, analysis, and interpretation of patient-reported outcomes (2nd ed.). 2007. Hoboken: Wiley-Blackwell.
- Carpenter JS, Bakoyannis G, Otte JL, et al. Validity, cut-points, and minimally important differences for two hot flash-related daily interference scales. Menopause. 2017;24(8):877–885.
- Harlow SD, Gass M, Hall JE, et al. Executive summary of the stages of reproductive aging workshop +10: addressing the unfinished agenda of staging reproductive aging. Climacteric. 2012;15(2):105–114.
- Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. JAMA. 2002;288(3):321–333.
- Prague JK, Roberts RE, Comninos AN, et al. Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2017;389(10081):1809–1820.